Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 261 articles:
HTML format
Text format



Single Articles


    September 2018
  1. GANDARA DR, von Pawel J, Mazieres J, Sullivan R, et al
    Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33043.
    PubMed     Text format     Abstract available


  2. SUN TY, Niu X, Chakraborty A, Neal JW, et al
    Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33046.
    PubMed     Text format    


  3. FERRER L, Giaj Levra M, Brevet M, Antoine M, et al
    A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33044.
    PubMed     Text format     Abstract available


  4. LIN JJ, Chin E, Yeap BY, Ferris LA, et al
    Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040.
    PubMed     Text format     Abstract available


  5. DESCARPENTRIES C, Lepretre F, Escande F, Kherrouche Z, et al
    Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33038.
    PubMed     Text format     Abstract available


  6. DENG W, Xu T, Wang Y, Xu Y, et al
    Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33036.
    PubMed     Text format     Abstract available


  7. LE-RADEMACHER J, Dahlberg S, Lee JJ, Adjei AA, et al
    Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33034.
    PubMed     Text format     Abstract available


  8. SWAMI U, Smith M, Zhang J
    Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    J Thorac Oncol. 2018;13:e183-e184.
    PubMed     Text format    


  9. MO X, Xu-Welliver M
    Response to the Letter to Editor re: The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e182-e183.
    PubMed     Text format    


  10. WALRAVEN I, Kwint M, Belderbos J
    The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e181-e182.
    PubMed     Text format    


  11. JIN B, Chuang X, Liu Y
    Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e174-e177.
    PubMed     Text format    


  12. DENG L, Kiedrowski LA, Ravera E, Cheng H, et al
    Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.
    J Thorac Oncol. 2018;13:e169-e172.
    PubMed     Text format    


  13. XU YJ, Shi ZL, Wang Z, Du L, et al
    Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e165-e168.
    PubMed     Text format    


  14. MARINO M, Visca P, Ottaviano M
    PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".
    J Thorac Oncol. 2018;13:1239-1241.
    PubMed     Text format    


    August 2018
  15. MORO M, Caiola E, Ganzinelli M, Zulato E, et al
    Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Aug 24. pii: S1556-0864(18)32988.
    PubMed     Text format     Abstract available


  16. BORGHAEI H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, et al
    24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942.
    PubMed     Text format     Abstract available


  17. LAUFER-GEVA S, Rozenblum AB, Twito T, Grinberg R, et al
    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
    J Thorac Oncol. 2018 Aug 16. pii: S1556-0864(18)30940.
    PubMed     Text format     Abstract available


  18. GUAITOLI G, Baldessari C, Tomasello C, Barbieri F, et al
    Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
    J Thorac Oncol. 2018;13:e152-e153.
    PubMed     Text format    


  19. FUJIOKA S, Kitajima T, Itotani R
    Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.
    J Thorac Oncol. 2018;13:e137-e139.
    PubMed     Text format    


  20. GARCIA CA, Dacic S, Villaruz LC
    Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e135-e136.
    PubMed     Text format    


  21. HAMANN HA, Pujol JL
    Introduction to the Special Section: The Experience and Impact of Lung Cancer Stigma.
    J Thorac Oncol. 2018;13:1053-1054.
    PubMed     Text format    


    July 2018
  22. SU S, Dong ZY, Xie Z, Yan LX, et al
    Strong PD-L1 expression predicts poor response and de novo resistance to EGFR TKIs among non-small cell lung cancer patients with EGFR mutation.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30811.
    PubMed     Text format     Abstract available


  23. ROACH MC, Robinson CG, DeWees TA, Ganachaud J, et al
    Stereotactic body radiation therapy (SBRT) for central early stage non-small cell lung cancer: results of a prospective phase I/II trial.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30812.
    PubMed     Text format     Abstract available


  24. ZHANG M, Wang Q, Ding Y, Wang G, et al
    Brief Report: CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 13. pii: S1556-0864(18)30785.
    PubMed     Text format     Abstract available


  25. KATO R, Hayashi H, Sano K, Handa K, et al
    Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with non-small cell lung cancer.
    J Thorac Oncol. 2018 Jul 11. pii: S1556-0864(18)30779.
    PubMed     Text format    


  26. OCCHIPINTI S, Dunn J, O'Connell DL, Garvey G, et al
    Lung Cancer Stigma Across the Social Network: Patients' and Caregivers' Perspectives.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30766.
    PubMed     Text format     Abstract available


  27. RIESS JW, Gandara DR, Frampton GM, Madison R, et al
    Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770.
    PubMed     Text format     Abstract available


  28. WILLIAMSON TJ, Choi AK, Kim JC, Garon EB, et al
    A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30769.
    PubMed     Text format     Abstract available


  29. PATIL T, Smith DE, Bunn PA, Aisner DL, et al
    The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30772.
    PubMed     Text format     Abstract available


  30. SEHGAL K, Peters MLB, VanderLaan PA, Rangachari D, et al
    Activity of brigatinib in the setting of alectinib resistance mediated by ALK-I1171S in ALK rearranged lung cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30771.
    PubMed     Text format    


  31. KINSEY E, Ajazi E, Wang X, Johnston MAM, et al
    Predictors of physical and functional loss in advanced stage lung cancer patients receiving platinum chemotherapy.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30676.
    PubMed     Text format     Abstract available


  32. LIU Y, Lusk CM, Cho MH, Silverman EK, et al
    Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30767.
    PubMed     Text format     Abstract available


  33. VELCHETI V, Madison R, Ali SM, Schrock AB, et al
    WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e122-e123.
    PubMed     Text format    


  34. ASSALLUM H, Harris K
    The Impact of the Eighth TNM Classification for Lung Cancer on the Endobronchial Ultrasound Procedure.
    J Thorac Oncol. 2018;13:e119-e120.
    PubMed     Text format    


  35. NAVARRO A, Martinez-Marti A, Felip E
    HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?
    J Thorac Oncol. 2018;13:874-876.
    PubMed     Text format    


    June 2018
  36. WU YL, Lu S, Lu Y, Zhou J, et al
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 29. pii: S1556-0864(18)30721.
    PubMed     Text format     Abstract available


  37. SHIUE K, Cerra-Franco A, Shapiro R, Estabrook N, et al
    Histology, tumor volume, and radiation dose predict outcomes in non-small cell lung cancer patients after stereotactic ablative radiotherapy.
    J Thorac Oncol. 2018 Jun 26. pii: S1556-0864(18)30716.
    PubMed     Text format     Abstract available


  38. LIN JJ, Zhu VW, Schoenfeld AJ, Yeap BY, et al
    Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.
    J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30714.
    PubMed     Text format     Abstract available


  39. WANG S, Yang L, Ci B, Maclean M, et al
    Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients.
    J Thorac Oncol. 2018 Jun 11. pii: S1556-0864(18)30687.
    PubMed     Text format     Abstract available


  40. HARATAKE N, Tagawa T, Hirai F, Toyokawa G, et al
    Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30681.
    PubMed     Text format    


  41. JONES CC, Mercaldo SF, Blume JD, Wenzlaff AS, et al
    Racial disparities in lung cancer survival: The contribution of stage, treatment, and ancestry.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30682.
    PubMed     Text format     Abstract available


  42. ROLFO C, Mack PC, Scagliotti GV, Baas P, et al
    IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680.
    PubMed     Text format     Abstract available


  43. GERAUD A, Mezquita L, Bigot F, Caramella C, et al
    Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30683.
    PubMed     Text format    


  44. PARK S, Ahn BC, Lim SW, Sun JM, et al
    Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30673.
    PubMed     Text format     Abstract available


  45. YEGYA-RAMAN N, Wang K, Kim S, Reyhan M, et al
    Dosimetric Predictors of Symptomatic Cardiac Events after Conventional-Dose Chemoradiation Therapy for Inoperable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30675.
    PubMed     Text format     Abstract available


  46. WOZNIAK AJ, Schwartz AG
    Risk of Second Lung Cancer in Patients With Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results Data.
    J Thorac Oncol. 2018;13:e106-e107.
    PubMed     Text format    


  47. MASCALCHI M, Sali L
    Risk of Second Lung Cancer in ITALUNG LDCT Screening.
    J Thorac Oncol. 2018;13:e105-e106.
    PubMed     Text format    


  48. WU CK, Kao SJ, Lai HC
    Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
    J Thorac Oncol. 2018;13:e103-e105.
    PubMed     Text format    


  49. BONOMI P, Blumenthal G, Ferris AS, Stewart DJ, et al
    Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
    J Thorac Oncol. 2018;13:748-751.
    PubMed     Text format    


  50. TSENG D, Padda SK, Wakelee HA
    Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:741-744.
    PubMed     Text format    


    May 2018
  51. GETTINGER S, Hellmann MD, Chow LQM, Borghaei H, et al
    Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 23. pii: S1556-0864(18)30628.
    PubMed     Text format     Abstract available


  52. HAMANN HA, Ver Hoeve ES, Carter-Harris L, Studts JL, et al
    Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.
    J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30627.
    PubMed     Text format     Abstract available


  53. FEHRENBACHER L, von Pawel J, Park K, Rittmeyer A, et al
    Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 16. pii: S1556-0864(18)30611.
    PubMed     Text format     Abstract available


  54. GADGEEL SM, Pennell NA, Fidler MJ, Halmos B, et al
    Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC).
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30600.
    PubMed     Text format     Abstract available


  55. SPIGEL DR, Chaft JE, Gettinger S, Chao BH, et al
    FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30603.
    PubMed     Text format     Abstract available


  56. WALTER JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, et al
    New subsolid pulmonary nodules in lung cancer screening: a brief report of the NELSON trial.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30605.
    PubMed     Text format     Abstract available


  57. KARANTH S, Rajan SS, Sharma G, Yamal JM, et al
    Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare-Based Study.
    J Thorac Oncol. 2018 May 10. pii: S1556-0864(18)30540.
    PubMed     Text format     Abstract available


  58. CODONY-SERVAT J, Garcia-Roman S, Molina-Vila MA, Bertran-Alamillo J, et al
    Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592.
    PubMed     Text format     Abstract available


  59. SMYTH RJ, Toomey SM, Sartori A, Hanrahan EO, et al
    Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30595.
    PubMed     Text format     Abstract available


  60. NAKAMURA R, Inage Y, Tobita R, Yoneyama S, et al
    Sarcopenia in resected non-small cell lung cancer: Effect on postoperative outcomes.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30597.
    PubMed     Text format     Abstract available


  61. KATZ SI, Hammer M, Bagley S, Aggarwal C, et al
    Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 5. pii: S1556-0864(18)30536.
    PubMed     Text format     Abstract available


  62. VOKES EE, Govindan R, Iscoe N, Hossain AM, et al
    The Impact of Staging by Positron Emission Tomography on Overall Survival and Progression-free Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 4. pii: S1556-0864(18)30589.
    PubMed     Text format     Abstract available


  63. GARASSINO MC, Gelibter AJ, Grossi F, Chiari R, et al
    Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553.
    PubMed     Text format     Abstract available


  64. TAMURA T, Akimoto E, Matsumoto C, Mori S, et al
    Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30554.
    PubMed     Text format    


  65. SAFIRI S, Ashrafi-Asgarabad A
    Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab: Methodological Issues.
    J Thorac Oncol. 2018;13:e85-e86.
    PubMed     Text format    


  66. WU B
    Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e84-e85.
    PubMed     Text format    


  67. HOYLE C, Dyer M
    Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e83-e84.
    PubMed     Text format    


  68. MARTINEZ VILA C, Garcia Garcia Y, Carcereny Costa E
    Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e77-e79.
    PubMed     Text format    


  69. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    "Teachable Moment" Interventions in Lung Cancer: Why Action Matters.
    J Thorac Oncol. 2018;13:603-605.
    PubMed     Text format    


  70. HERMAN M, Warkentin MT, Shepshelovich D, Latifovic L, et al
    Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All.
    J Thorac Oncol. 2018;13:601-602.
    PubMed     Text format    


    April 2018
  71. DUDNIK E, Peled N, Nechushtan H, Wollner M, et al
    BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors.
    J Thorac Oncol. 2018 Apr 30. pii: S1556-0864(18)30552.
    PubMed     Text format     Abstract available


  72. ANDREANO A, Peake MD, Janes SM, Valsecchi MG, et al
    The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.
    J Thorac Oncol. 2018 Apr 26. pii: S1556-0864(18)30550.
    PubMed     Text format     Abstract available


  73. VAN KEMPEN LC, Wang H, Aguirre ML, Spatz A, et al
    Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30548.
    PubMed     Text format    


  74. LI Z, Shen L, Ding D, Huang J, et al
    Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30542.
    PubMed     Text format     Abstract available


  75. MUNARI E, Zamboni G, Lunardi G, Marchionni L, et al
    PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30543.
    PubMed     Text format     Abstract available


  76. VAN VEGGEL B, de Langen AJ, Hashemi S, Monkhorst K, et al
    Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.
    J Thorac Oncol. 2018 Apr 24. pii: S1556-0864(18)30538.
    PubMed     Text format     Abstract available


  77. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30537.
    PubMed     Text format     Abstract available


  78. WADE S, Weber M, Caruana M, Kang YJ, et al
    Estimating the cost-effectiveness of lung cancer screening with low dose computed tomography for high risk smokers in Australia.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30531.
    PubMed     Text format     Abstract available


  79. DONINGTON JS, Kim YT, Tong B, Moreira AL, et al
    Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30508.
    PubMed     Text format     Abstract available


  80. OWADA-OZAKI Y, Muto S, Takagi H, Inoue T, et al
    Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30509.
    PubMed     Text format     Abstract available


  81. OSTIOS-GARCIA L, Faig J, Leonardi GC, Adeni AE, et al
    Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30270.
    PubMed     Text format     Abstract available


  82. SANDBERG Y, den Bakker MA
    Small cell lung cancer presenting as carcinocythemia.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30269.
    PubMed     Text format    


  83. MA Y, Zheng X, Zhao H, Fang W, et al
    First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30264.
    PubMed     Text format     Abstract available


  84. CARR SR, Akerley W, Cannon-Albright L
    Genetic Contribution to Non-Squamous, Non-Small Cell Lung Cancer in Non-Smokers.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30263.
    PubMed     Text format     Abstract available


  85. WATANABE J, Furuya N, Fujiwara Y
    Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.
    J Thorac Oncol. 2018;13:e66-e69.
    PubMed     Text format    


  86. MORMILE R
    Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
    J Thorac Oncol. 2018;13:e65-e66.
    PubMed     Text format    


  87. SAFIRI S
    Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.
    J Thorac Oncol. 2018;13:e61.
    PubMed     Text format    


  88. SANDFELD-PAULSEN B, Aggerholm-Pedersen N
    Response to Safri: "Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity".
    J Thorac Oncol. 2018;13:e61-e62.
    PubMed     Text format    


  89. MASAI K, Motoi N
    Response to Letter to the Editor Titled "Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer".
    J Thorac Oncol. 2018;13:e58-e59.
    PubMed     Text format    


  90. MANSORI K, Ayubi E, Safiri S
    Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2018;13:e57-e58.
    PubMed     Text format    


  91. SUN JM
    Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2018;13:e56-e57.
    PubMed     Text format    


  92. COSTANTINI A, Cadranel J
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e55-e56.
    PubMed     Text format    


  93. LEVY A, Hendriks LE, Faivre-Finn C
    Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?
    J Thorac Oncol. 2018;13:475-477.
    PubMed     Text format    


    March 2018
  94. GAJRA A, Zemla TJ, Jatoi A, Feliciano JL, et al
    Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients.
    J Thorac Oncol. 2018 Mar 30. pii: S1556-0864(18)30254.
    PubMed     Text format     Abstract available


  95. LI Y, Liu B, Connolly ID, Kakusa BW, et al
    Brief Report: Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    J Thorac Oncol. 2018 Mar 28. pii: S1556-0864(18)30222.
    PubMed     Text format     Abstract available


  96. SHIBAHARA D, Tanaka K, Iwama E, Kubo N, et al
    Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 26. pii: S1556-0864(18)30215.
    PubMed     Text format     Abstract available


  97. LEE CK, Lord S, Marschner I, Wu YL, et al
    The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer.
    J Thorac Oncol. 2018 Mar 23. pii: S1556-0864(18)30212.
    PubMed     Text format     Abstract available


  98. FLORES R, Taioli E, Yankelevitz DF, Becker BJ, et al
    Initiative for Early Lung Cancer Research on Treatment: Development of Study Design and Pilot Implementation.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30211.
    PubMed     Text format     Abstract available


  99. GETTINGER SN, Wurtz A, Goldberg SB, Rimm D, et al
    Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210.
    PubMed     Text format     Abstract available


  100. MAENG CH, Song JU, Shim SR, Lee J, et al
    The Role of Prophylactic Cranial Irradiation in Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30180.
    PubMed     Text format     Abstract available


  101. PARRA ER, Villalobos P, Zhang J, Behrens C, et al
    Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30182.
    PubMed     Text format     Abstract available


  102. ROCCO G, Pennazza G, Santonico M, Longo F, et al
    Breathprinting and early diagnosis of lung cancer.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30183.
    PubMed     Text format     Abstract available


  103. SPIGEL DR, Reynolds C, Waterhouse D, Garon EB, et al
    Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176.
    PubMed     Text format     Abstract available


  104. TOYOOKA S, Okumura N, Nakamura H, Nakata M, et al
    A multi-center randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer.
    J Thorac Oncol. 2018 Mar 2. pii: S1556-0864(18)30168.
    PubMed     Text format     Abstract available


  105. YASUDA Y, Ozasa H, Kim YH
    PD-L1 Expression in Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e40-e41.
    PubMed     Text format    


  106. CHO JH, Sun JM, Lee SH, Ahn JS, et al
    Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e34-e36.
    PubMed     Text format    


  107. RANDHAWA S, Moore RF, DiSesa V, Kaiser L, et al
    Role of Thoracic Surgeons in Lung Cancer Screening: Opportune Time for Involvement.
    J Thorac Oncol. 2018;13:298-300.
    PubMed     Text format    


    February 2018
  108. GIROUX DJ, Van Schil P, Asamura H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.
    J Thorac Oncol. 2018 Feb 21. pii: S1556-0864(18)30131.
    PubMed     Text format     Abstract available


  109. WEN J, Liu H, Wang L, Wang X, et al
    Potentially Functional variants of ATG16L2 predict radiation pneumonitis and outcomes in patients with non-small cell lung cancer after definitive radiotherapy.
    J Thorac Oncol. 2018 Feb 15. pii: S1556-0864(18)30103.
    PubMed     Text format     Abstract available


  110. VAN DE GOOR R, van Hooren M, Dingemans AM, Kremer B, et al
    Training and validating a portable electronic nose for lung cancer screening.
    J Thorac Oncol. 2018 Feb 6. pii: S1556-0864(18)30093.
    PubMed     Text format     Abstract available


  111. EATON KD, Romine PE, Goodman GE, Thornquist MD, et al
    Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
    J Thorac Oncol. 2018 Feb 2. pii: S1556-0864(18)30090.
    PubMed     Text format     Abstract available


  112. MORGENSZTERN D, Samson P, Waqar SN, Devarakonda S, et al
    Early mortality in patients undergoing adjuvant chemotherapy for non-small-cell lung cancer.
    J Thorac Oncol. 2018 Feb 1. pii: S1556-0864(18)30036.
    PubMed     Text format     Abstract available


  113. ASHRAFI-ASGARABAD A, Safiri S
    Prognostic Value of Primary Tumor Volume Changes on Kilovoltage Onboard Cone Beam Computed Tomography during Definitive Chemoradiotherapy for stage III Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2018;13:e26-e27.
    PubMed     Text format    


  114. LEONE A
    C797S and T790M EGFR Mutations in Non-Small Cell Lung Cancer: In Trans or in Separate Clones?
    J Thorac Oncol. 2018;13:e21-e22.
    PubMed     Text format    


  115. GAZDAR AF
    Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
    J Thorac Oncol. 2018;13:148-150.
    PubMed     Text format    


    January 2018
  116. KATZMAN D, Wu S, Sterman DH
    Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30079.
    PubMed     Text format     Abstract available


  117. WOLFF HB, Alberts L, Kastelijn EA, Lissenberg-Witte BI, et al
    Differences in longitudinal health utility between stereotactic body radiation therapy and surgery in stage I non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30083.
    PubMed     Text format     Abstract available


  118. HUBBELING HG, Schapira EF, Horick NK, Goodwin KEH, et al
    Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jan 26. pii: S1556-0864(18)30039.
    PubMed     Text format     Abstract available


  119. STONE E, Jett J, Warren G, Cummings KM, et al
    Cannabis Use, Lung Cancer, and Related Issues.
    J Thorac Oncol. 2018 Jan 24. pii: S1556-0864(18)30038.
    PubMed     Text format     Abstract available


  120. LINDEMAN NI, Cagle PT, Aisner DL, Arcila ME, et al
    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and
    J Thorac Oncol. 2018 Jan 23. pii: S1556-0864(17)33071.
    PubMed     Text format     Abstract available


  121. HOUSTON KA, Mitchell KA, King J, White A, et al
    Histologic Lung Cancer Incidence Rates and Trends vary by Race/Ethnicity and Residential County.
    J Thorac Oncol. 2018 Jan 19. pii: S1556-0864(18)30003.
    PubMed     Text format     Abstract available


  122. NYGARD L, Vogelius IR, Fischer BM, Kjaer A, et al
    A competing risk model of first failure site after definitive (chemo) radiation therapy for locally advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 18. pii: S1556-0864(18)30006.
    PubMed     Text format     Abstract available


  123. MAROM EM, Ofek E, Bekker E, Onn A, et al
    Tattoo Induced False Positive FDG PET-CT Interpretation while Staging for Lung Cancer.
    J Thorac Oncol. 2018 Jan 17. pii: S1556-0864(18)30005.
    PubMed     Text format    


  124. RICCIUTI B, Metro G, Brambilla M, Ludovini V, et al
    Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.
    J Thorac Oncol. 2018;13:e9-e12.
    PubMed     Text format    


  125. MCCANN B, Clark B
    Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor-Mutated Lung Cancer Treated with Two Cycles of Erlotinib.
    J Thorac Oncol. 2018;13:e7-e8.
    PubMed     Text format    


  126. ZHANG X, Zheng X
    Reply to "Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?"
    J Thorac Oncol. 2018;13:e16.
    PubMed     Text format    


  127. MORMILE R
    Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?
    J Thorac Oncol. 2018;13:e15.
    PubMed     Text format    


  128. DONG ZY, Zhang C, Li YF, Su J, et al
    Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
    J Thorac Oncol. 2018;13:85-96.
    PubMed     Text format     Abstract available


  129. BUCCIARELLI PR, Tan KS, Chudgar NP, Brandt W, et al
    BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
    J Thorac Oncol. 2018;13:73-84.
    PubMed     Text format     Abstract available


  130. PATIL NS, Righi L, Koeppen H, Zou W, et al
    Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2018;13:124-133.
    PubMed     Text format     Abstract available


  131. NOONAN SA, Patil T, Gao D, King GG, et al
    Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
    J Thorac Oncol. 2018;13:134-138.
    PubMed     Text format     Abstract available


    December 2017
  132. PILOTTO S, Sperduti I, Leuzzi G, Chiappetta M, et al
    Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33101.
    PubMed     Text format     Abstract available


  133. WU SP, Liao RQ, Tu HY, Wang WJ, et al
    Stromal PD-L1+regulatory T cells and PD-1+CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33102.
    PubMed     Text format     Abstract available


  134. ROBIN TP, Camidge DR, Stuhr K, Nath SK, et al
    Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33107.
    PubMed     Text format     Abstract available


  135. MILLER ED, Fisher JL, Haglund KE, Grecula JC, et al
    The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33108.
    PubMed     Text format     Abstract available


  136. FELIP E, Barlesi F, Besse B, Chu Q, et al
    Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 13. pii: S1556-0864(17)33083.
    PubMed     Text format     Abstract available


  137. TSENG YH, Ho HL, Lai CR, Luo YH, et al
    Brief Report: PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33079.
    PubMed     Text format     Abstract available


  138. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Influence of Ground-Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33080.
    PubMed     Text format     Abstract available


  139. STIEFEL F, Bourquin C
    Adverse Effects of "Teachable Moment" Interventions in Lung Cancer: Why Prudence Matters.
    J Thorac Oncol. 2017 Dec 11. pii: S1556-0864(17)32862.
    PubMed     Text format    


  140. STABILE LP, Farooqui M, Kanterewicz B, Abberbock S, et al
    Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33076.
    PubMed     Text format     Abstract available


  141. FUJIMOTO D, Sato Y, Uehara K, Ishida K, et al
    Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33072.
    PubMed     Text format     Abstract available


  142. HOTTA K, Aoe K, Kozuki T, Ohashi K, et al
    A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 4. pii: S1556-0864(17)33065.
    PubMed     Text format     Abstract available


  143. BOLZACCHINI E, Tuzi A, Gobba S, Pinotti G, et al
    Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.
    J Thorac Oncol. 2017;12:e208-e210.
    PubMed     Text format    


  144. GU F, Cheung L, Katki H, Caporaso N, et al
    Response to Safiri et al. "Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening".
    J Thorac Oncol. 2017;12:e208.
    PubMed     Text format    


  145. SAFIRI S, Mansourpour H, Ayubi E
    Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers For Lung Cancer Screening.
    J Thorac Oncol. 2017;12:e207.
    PubMed     Text format    


  146. NAKANISHI Y, Masuda S, Iida Y, Takahashi N, et al
    Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
    J Thorac Oncol. 2017;12:e202-e204.
    PubMed     Text format    



  147. Erratum to: Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim S-M, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Postive Human Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(3):491-500.
    J Thorac Oncol. 2017;12:1859.
    PubMed     Text format    


  148. WATZA D, Schwartz AG
    Addressing Underrepresented Populations in Lung Cancer Research: The Hispanic/Latino Lung Cancer Registry Identifies Distinct Mutation Profiles for NSCLC.
    J Thorac Oncol. 2017;12:1744-1745.
    PubMed     Text format    


    November 2017
  149. SOCINSKI MA, Obasaju C, Gandara D, Hirsch FR, et al
    Current and Emergent Therapy Options for Advanced Squamous-Cell Lung Cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33053.
    PubMed     Text format     Abstract available


  150. HENDRY S, Byrne DJ, Wright GM, Young RJ, et al
    Comparison of four PD-L1 immunohistochemical assays in lung cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33054.
    PubMed     Text format     Abstract available


  151. TANIZAKI J, Haratani K, Hayashi H, Chiba Y, et al
    Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab.
    J Thorac Oncol. 2017 Nov 20. pii: S1556-0864(17)33008.
    PubMed     Text format     Abstract available


  152. YANKELEVITZ DF
    CT Screening for Lung Cancer: Successful Trial, but Failed Understanding.
    J Thorac Oncol. 2017 Nov 18. pii: S1556-0864(17)32767.
    PubMed     Text format    


  153. RECK M, Taylor F, Penrod JR, DeRosa M, et al
    Impact of Nivolumab Versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients With Advanced Squamous Non-Small Cell Lung Cancer: Results From the CheckMate 017 Study.
    J Thorac Oncol. 2017 Nov 9. pii: S1556-0864(17)32878.
    PubMed     Text format     Abstract available


  154. FERRARA R, Auger N, Auclin E, Besse B, et al
    Clinical and translational implications of RET rearrangements in non-small cell lung cancer.
    J Thorac Oncol. 2017 Nov 8. pii: S1556-0864(17)32866.
    PubMed     Text format     Abstract available


  155. RICORDEL C, Llamas-Gutierrez F, Chiforeanu D, Lena H, et al
    Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.
    J Thorac Oncol. 2017;12:e184-e186.
    PubMed     Text format    


  156. LEE JS, Hur JY, Kim HJ, Lee KY, et al
    A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e179-e181.
    PubMed     Text format    


  157. HENNINGFIELD MF, Adjei AA
    Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.
    J Thorac Oncol. 2017;12:1603-1605.
    PubMed     Text format    


    October 2017
  158. PARK SE, Lee SH, Ahn JS, Ahn MJ, et al
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32850.
    PubMed     Text format     Abstract available


  159. WU B, Gu X, Zhang Q
    Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32851.
    PubMed     Text format     Abstract available


  160. SANDFELD-PAULSEN B, Meldgaard P, Aggerholm-Pedersen N
    Comorbidity in lung cancer: A prospective cohort study of self-reported versus register-based comorbidity.
    J Thorac Oncol. 2017 Oct 19. pii: S1556-0864(17)32788.
    PubMed     Text format     Abstract available


  161. PINATO DJ, Newsom-Davis T
    Regression of para-neoplastic rash following lung cancer chemotherapy.
    J Thorac Oncol. 2017 Oct 14. pii: S1556-0864(17)32786.
    PubMed     Text format    


  162. TOKACA N, Barth S, O'Brien M, Bhosle J, et al
    Molecular adequacy of image-guided rebiopsies for molecular retesting in advanced non-small cell lung cancer: a single centre experience.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32760.
    PubMed     Text format     Abstract available


  163. THAKUR MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, et al
    Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology and End Results (SEER) Data.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32766.
    PubMed     Text format     Abstract available


  164. SHUKUYA T, Patel S, Shane-Carson K, He K, et al
    Lung Cancer Patients with Germline Mutations detected by next generation sequencing and/or liquid biopsy.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32764.
    PubMed     Text format    


  165. SHOLL LM
    Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing.
    J Thorac Oncol. 2017;12:1464-1466.
    PubMed     Text format    


    September 2017
  166. SUN JM, Noh JM, Oh D, Kim HK, et al
    Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32708.
    PubMed     Text format     Abstract available


  167. MEYER M, Vliegenthart R, Henzler T, Buergy D, et al
    Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32713.
    PubMed     Text format     Abstract available


  168. BOYER MJ, Williams CD, Harpole DH, Onaitis MW, et al
    Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.
    J Thorac Oncol. 2017 Sep 23. pii: S1556-0864(17)32706.
    PubMed     Text format     Abstract available


  169. ALMODOVAR K, Iams WT, Meador CB, Zhao Z, et al
    Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse.
    J Thorac Oncol. 2017 Sep 22. pii: S1556-0864(17)32705.
    PubMed     Text format     Abstract available


  170. TERAOKA S, Fujimoto D, Morimoto T, Kawachi H, et al
    Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study.
    J Thorac Oncol. 2017 Sep 19. pii: S1556-0864(17)30825.
    PubMed     Text format     Abstract available


  171. HIGGINS KA, Pillai RN, Chen Z, Tian S, et al
    Concomitant chemotherapy and radiotherapy with SBRT Boost for Unresectable, Stage III Non-small Cell Lung Cancer: A phase I Study.
    J Thorac Oncol. 2017 Sep 12. pii: S1556-0864(17)30734.
    PubMed     Text format     Abstract available


  172. GIMBRONE NT, Sarcar B, Gordian ER, Rivera JI, et al
    Brief Report: Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.
    J Thorac Oncol. 2017 Sep 11. pii: S1556-0864(17)30731.
    PubMed     Text format     Abstract available


  173. MASAI K, Sakurai H, Sukeda A, Suzuki S, et al
    Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30727.
    PubMed     Text format     Abstract available


  174. RUSTHOVEN CG, Kavanagh BD
    Prophylactic Cranial Irradiation (PCI) vs Active MRI Surveillance for Small-Cell Lung Cancer: The Case for Equipoise.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30728.
    PubMed     Text format     Abstract available


  175. SEPESI B, Correa AM, Dmitrovsky E, Liu X, et al
    Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues".
    J Thorac Oncol. 2017;12:e150-e151.
    PubMed     Text format    


  176. SAFIRI S, Khazaei S, Ayubi E
    The Influence of Body Mass Index on Overall Survival following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e149-e150.
    PubMed     Text format    


  177. KHUNGER M, Calabrese C, Kontzias A, Velcheti V, et al
    To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.
    J Thorac Oncol. 2017;12:e147-e149.
    PubMed     Text format    


  178. KOMATSU T, Nakamura K, Kawase A
    Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    J Thorac Oncol. 2017;12:e143-e144.
    PubMed     Text format    


  179. FUNAZO T, Nomizo T, Kim YH
    Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    J Thorac Oncol. 2017;12:e140-e141.
    PubMed     Text format    


  180. GORTAIS H, Daniel C, Bidard FC, Jeannot E, et al
    T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
    J Thorac Oncol. 2017;12:e138-e139.
    PubMed     Text format    


  181. EZE C, Roengvoraphoj O, Manapov F
    Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role.
    J Thorac Oncol. 2017;12:e137-e138.
    PubMed     Text format    


  182. VAN SCHIL PE
    Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?
    J Thorac Oncol. 2017;12:1338-1340.
    PubMed     Text format    


    August 2017
  183. WALD P, Mo X, Barney C, Gunderson D, et al
    Prognostic value of primary tumor volume changes on kV-CBCT during definitive chemoradiotherapy for stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30685.
    PubMed     Text format     Abstract available


  184. ARULANANDA S, Do H, Musafer A, Mitchell P, et al
    Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30681.
    PubMed     Text format     Abstract available


  185. DAVID EA, Clark JM, Cooke DT, Melnikow J, et al
    The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30683.
    PubMed     Text format     Abstract available


  186. GU F, Cheung LC, Freedman ND, Katki HA, et al
    Potential impact of including Time to First Cigarette into risk models for selecting ever-smokers for lung-cancer screening.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30664.
    PubMed     Text format     Abstract available


  187. LIN JJ, Shaw AT
    Recent Advances in Targeting ROS1 in Lung Cancer.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30668.
    PubMed     Text format     Abstract available


  188. KONO M, Allen PK, Lin SH, Wei X, et al
    Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.
    J Thorac Oncol. 2017 Aug 10. pii: S1556-0864(17)30661.
    PubMed     Text format     Abstract available


  189. XIZHAO S, Wei J, Haiqing C, Fan Y, et al
    Validation of the stage groupings in the 8th edition of the TNM classification for lung cancer.
    J Thorac Oncol. 2017 Aug 3. pii: S1556-0864(17)30659.
    PubMed     Text format     Abstract available


  190. SAFIRI S, Ayubi E
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e130-e131.
    PubMed     Text format    


  191. KIMURA H, Tounai Y, Nagato K, Morimoto JI, et al
    A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e128-e130.
    PubMed     Text format    


  192. YANAGISAWA S, Miyauchi E, Ichinose M
    Numb Chin Syndrome: An Ominous Sign of Lung Cancer.
    J Thorac Oncol. 2017;12:e114-e116.
    PubMed     Text format    


  193. SHOJAEE S, Vachani A, Nana-Sinkam P
    The Financial Implications of Lung Cancer Screening: Is It Worth It?
    J Thorac Oncol. 2017;12:1177-1179.
    PubMed     Text format    


  194. STONE E, Slatore CG
    The Obesity Paradox-What Does It Mean for Lung Cancer Surgery?
    J Thorac Oncol. 2017;12:1174-1176.
    PubMed     Text format    


    July 2017
  195. FURUTA H, Yoshida T, Shimizu J, Tomita N, et al
    Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 31. pii: S1556-0864(17)30656.
    PubMed     Text format    


  196. ZHANG X, Liu Y, Shao H, Zheng X, et al
    Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications.
    J Thorac Oncol. 2017 Jul 27. pii: S1556-0864(17)30619.
    PubMed     Text format     Abstract available


  197. LI C, Huang C, Mok TS, Zhuang W, et al
    Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer.
    J Thorac Oncol. 2017 Jul 24. pii: S1556-0864(17)30612.
    PubMed     Text format     Abstract available


  198. NORSKOV MS, Dahl M, Tybjaerg-Hansen A
    Genetic variation in GSTP1, lung function, risk of lung cancer and mortality in 66,000 individuals.
    J Thorac Oncol. 2017 Jul 21. pii: S1556-0864(17)30605.
    PubMed     Text format     Abstract available


  199. LOGANADANE G, Hendriks L, Le Pechoux C, Levy A, et al
    The current role of whole brain radiation therapy in non-small cell lung cancer patients.
    J Thorac Oncol. 2017 Jul 18. pii: S1556-0864(17)30585.
    PubMed     Text format     Abstract available


  200. CHO BC, Kim DW, Bearz A, Laurie SA, et al
    ASCEND-8: A Randomized Phase 1 Study of Ceritinib 450 mg or 600 mg Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2017 Jul 17. pii: S1556-0864(17)30578.
    PubMed     Text format     Abstract available


  201. SHLOMI D, Abud M, Liran O, Bar J, et al
    Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.
    J Thorac Oncol. 2017 Jul 11. pii: S1556-0864(17)30573.
    PubMed     Text format     Abstract available


  202. YANG JC, Ou SI, De Petris L, Gadgeel S, et al
    Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 5. pii: S1556-0864(17)30570.
    PubMed     Text format     Abstract available


  203. YOSHIDA R, Sasaki T, Ohsaki Y
    EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.
    J Thorac Oncol. 2017;12:e92-e93.
    PubMed     Text format    


    June 2017
  204. GORE EM, Hu C, Sun AY, Grimm DF, et al
    Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC): NRG Oncology RTOG 0937.
    J Thorac Oncol. 2017 Jun 22. pii: S1556-0864(17)30468.
    PubMed     Text format     Abstract available


  205. GUPTA A, Saltarski JM, White MA, Scaglioni PP, et al
    Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
    J Thorac Oncol. 2017 Jun 21. pii: S1556-0864(17)30466.
    PubMed     Text format     Abstract available


  206. BARON AE, Kako S, Feser WJ, Malinowski H, et al
    Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.
    J Thorac Oncol. 2017 Jun 17. pii: S1556-0864(17)30461.
    PubMed     Text format     Abstract available


  207. EDELMAN MJ, Hu C, Le QT, Donington JS, et al
    Randomized Phase II Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-small Cell Lung Cancer: NRG Oncology RTOG 0839.
    J Thorac Oncol. 2017 Jun 16. pii: S1556-0864(17)30459.
    PubMed     Text format     Abstract available


  208. EVISON M, Clive A, Castle L, Powell H, et al
    Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
    J Thorac Oncol. 2017 Jun 14. pii: S1556-0864(17)30448.
    PubMed     Text format     Abstract available


  209. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Clinical and Pathological Staging Validation in the Eighth Edition of TNM Classification for Lung Cancer: Correlation Between Solid Size on Thin-section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification.
    J Thorac Oncol. 2017 Jun 13. pii: S1556-0864(17)30444.
    PubMed     Text format     Abstract available


  210. SACHER AG, Komatsubara KM, Oxnard GR
    Application of plasma genotyping technologies in non-small cell lung cancer: a practical review.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30441.
    PubMed     Text format     Abstract available


  211. RANGACHARI D, Le X, Shea M, Huberman MS, et al
    Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30440.
    PubMed     Text format    


  212. LEVENTAKOS K, Peikert T, Midthun D, Molina JR, et al
    Management of multifocal lung cancer: Results of a survey.
    J Thorac Oncol. 2017 Jun 2. pii: S1556-0864(17)30421.
    PubMed     Text format     Abstract available


  213. CHIC N, Mayo-de-Las-Casas C, Reguart N
    Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    J Thorac Oncol. 2017;12:e78-e80.
    PubMed     Text format    


  214. HSU CL, Chen KY, Kuo SW, Chang YL, et al
    Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    J Thorac Oncol. 2017;12:e75-e76.
    PubMed     Text format    


  215. CHEN CW, Kuo CW, Chen YL, Ho CL, et al
    Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
    J Thorac Oncol. 2017;12:e72-e74.
    PubMed     Text format    


  216. UGUEN A, Schick U, Quere G
    A Rare Case of ROS1 and ALK Double Rearranged Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e71-e72.
    PubMed     Text format    


  217. THUNNISSEN E, Witte BI, Noguchi M, Yatabe Y, et al
    Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases."
    J Thorac Oncol. 2017;12:e70-e71.
    PubMed     Text format    


  218. SABOUR S
    Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer; Statistical Issue on Reproducibility Analysis.
    J Thorac Oncol. 2017;12:e69.
    PubMed     Text format    


  219. GREEN S, Dawe DE, Banerji S
    Immune Signatures of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:913-915.
    PubMed     Text format    


  220. FARUKI H, Mayhew GM, Serody JS, Hayes DN, et al
    Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    J Thorac Oncol. 2017;12:943-953.
    PubMed     Text format     Abstract available


  221. SHAIKH F, Zauderer MG, von Reibnitz D, Wu AJ, et al
    Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2017;12:993-1000.
    PubMed     Text format     Abstract available


  222. SCHROCK AB, Li SD, Frampton GM, Suh J, et al
    Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    J Thorac Oncol. 2017;12:932-942.
    PubMed     Text format     Abstract available


  223. VERRI C, Borzi C, Holscher T, Dugo M, et al
    Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.
    J Thorac Oncol. 2017;12:922-931.
    PubMed     Text format     Abstract available


    May 2017
  224. SEPESI B, Gold KA, Correa AM, Heymach JV, et al
    The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30390.
    PubMed     Text format     Abstract available


  225. WAN R, Wang Z, Lee JJ, Wang S, et al
    Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small-cell lung cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30391.
    PubMed     Text format     Abstract available


  226. KARLSSON A, Brunnstrom H, Micke P, Veerla S, et al
    Gene expression profiling of large cell lung cancer links transcriptional phenotypes to the new histological WHO2015 classification.
    J Thorac Oncol. 2017 May 20. pii: S1556-0864(17)30388.
    PubMed     Text format     Abstract available


  227. FELLER-KOPMAN D, Liu S, Geisler BP, DeCamp MM, et al
    Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30364.
    PubMed     Text format     Abstract available


  228. CRESSMAN S, Peacock SJ, Tammemagi MC, Evans WK, et al
    The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30354.
    PubMed     Text format     Abstract available


  229. ADAMS MN, Burgess JT, He Y, Gately K, et al
    Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer.
    J Thorac Oncol. 2017 May 6. pii: S1556-0864(17)30351.
    PubMed     Text format     Abstract available


  230. GONG X, Li X, Jiang T, Xie H, et al
    Combined Radiotherapy and anti-PD-L1 antibody Synergistically Enhances Anti-tumor Effect in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 3. pii: S1556-0864(17)30343.
    PubMed     Text format     Abstract available


  231. MIYAUCHI E, Ichinose M, Inoue A
    Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.
    J Thorac Oncol. 2017;12:e59-e61.
    PubMed     Text format    


  232. DAHELE M, Damhuis R
    The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer.
    J Thorac Oncol. 2017;12:e58-e59.
    PubMed     Text format    


  233. RICCIUTI B, Metro G, Baglivo S, Colabrese D, et al
    Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e51-e55.
    PubMed     Text format    


  234. OGATA H, Yamamoto Y, Harada T, Nakanishi Y, et al
    Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e46-e47.
    PubMed     Text format    


  235. ABDUL KARIM L, Wang P, Chahine J, Kallakury B, et al
    Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress.
    J Thorac Oncol. 2017;12:e45.
    PubMed     Text format    


  236. THORNE-NUZZO T, Williams C, Catallini A, Clements J, et al
    A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    J Thorac Oncol. 2017;12:804-813.
    PubMed     Text format     Abstract available


  237. ZHAO ZR, Situ DR, Lau RWH, Mok TSK, et al
    Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.
    J Thorac Oncol. 2017;12:890-896.
    PubMed     Text format     Abstract available


  238. RANGACHARI D, VanderLaan PA, Shea M, Le X, et al
    Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:878-883.
    PubMed     Text format     Abstract available


  239. SAXON JA, Sholl LM, Janne PA
    EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
    J Thorac Oncol. 2017;12:884-889.
    PubMed     Text format     Abstract available


  240. REULING EMBP, Dickhoff C, Daniels JMA
    Treatment of Bronchial Carcinoid Tumors: Is Surgery Really Necessary?
    J Thorac Oncol. 2017;12:e57-e58.
    PubMed     Text format    


  241. LANTUEJOUL S, Le Stang N, Damiola F, Scherpereel A, et al
    PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
    J Thorac Oncol. 2017;12:778-781.
    PubMed     Text format    


  242. SAVIC S, Rothschild S, Bubendorf L
    Lonely Driver ROS1.
    J Thorac Oncol. 2017;12:776-777.
    PubMed     Text format    


  243. BOTLING J, Sandelin M
    Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction.
    J Thorac Oncol. 2017;12:770-772.
    PubMed     Text format    


    April 2017
  244. CHANSKY K, Detterbeck FC, Nicholson AG, Rusch VW, et al
    The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30340.
    PubMed     Text format     Abstract available


  245. RECK M, Blais N, Juhasz E, Gorbunova V, et al
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30338.
    PubMed     Text format     Abstract available


  246. JENKINS S, C-H Yang J, Ramalingam SS, Yu K, et al
    Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 17. pii: S1556-0864(17)30280.
    PubMed     Text format     Abstract available


  247. SOO RA, Adjei AA
    Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.
    J Thorac Oncol. 2017;12:602-606.
    PubMed     Text format    


  248. GARDNER EE, Poirier JT, Rudin CM
    Histone Code Aberrancies in Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:599-601.
    PubMed     Text format    


  249. PETERS MLB, Costa DB, Rangachari D
    Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.
    J Thorac Oncol. 2017;12:e35-e36.
    PubMed     Text format    


  250. LAINE A, Choy H
    Single-Fraction Carbon Ion Radiotherapy for Early-Stage NSCLC-The Future Is Now.
    J Thorac Oncol. 2017;12:610-611.
    PubMed     Text format    


  251. JOHN T, Russell PA, Thapa B
    Is Mesothelioma in China Rare or Misdiagnosed?
    J Thorac Oncol. 2017;12:607-609.
    PubMed     Text format    


    March 2017
  252. SENAN S, Louie AV
    Correlation, Causation and Confounding-What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?
    J Thorac Oncol. 2017 Mar 22. pii: S1556-0864(17)30127.
    PubMed     Text format    


  253. YANAGAWA N
    The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma: Author's Reply.
    J Thorac Oncol. 2017;12:e25-e26.
    PubMed     Text format    


  254. MAO R, Chen C, Fei K
    The Clinical Implications and Thoughts on Different Patterns in Resected Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:e24-e25.
    PubMed     Text format    


    February 2017
  255. WARTH A, Beasley MB, Mino-Kenudson M
    Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS).
    J Thorac Oncol. 2017;12:176-178.
    PubMed     Text format    


  256. HEIGENER DF, Reck M
    PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
    J Thorac Oncol. 2017;12:171-172.
    PubMed     Text format    


    January 2017
  257. BASSE C, Merveilleux du Vignaux C, Girard N
    Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System.
    J Thorac Oncol. 2017;12:e8-e9.
    PubMed     Text format    


  258. RUSSO A, Franchina T, Ricciardi GRR, Adamo V, et al
    Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
    J Thorac Oncol. 2017;12:e6-e8.
    PubMed     Text format    


  259. LI YS, Jiang BY, Yang JJ, Tu HY, et al
    Little Influence of Bevacizumab in Diagnosis of Leptomeningeal Metastases in Current Study.
    J Thorac Oncol. 2017;12:e5-e6.
    PubMed     Text format    


  260. VENNIYOOR A
    False-Negative MRI Findings for Leptomeningeal Metastases with Use of Bevacizumab.
    J Thorac Oncol. 2017;12:e5.
    PubMed     Text format    


  261. SOLOMON B
    Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC.
    J Thorac Oncol. 2017;12:9-11.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: